NASDAQ:PDSB - PDS Biotechnology Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $7.62
Forecasted Upside: 70.09 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
0 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$4.48 As of 05/10/2021 02:36 PM ET

▼ -0.36 (-7.44%)

1 month | 3 months | 12 months

Get New PDS Biotechnology Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for PDSB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PDSB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$7.62

▲ +70.09% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for PDS Biotechnology in the last 3 months. The average price target is $7.62, with a high forecast of $10.00 and a low forecast of $6.50. The average price target represents a 70.09% upside from the last price of $4.48.

Buy

The current consensus among 5 investment analysts is to buy stock in PDS Biotechnology.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/17/2019

0 strong buy ratings
2 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/15/2020

0 strong buy ratings
3 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/15/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/13/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

11/11/2020

0 strong buy ratings
4 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

2/9/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/10/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/10/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/10/2021	Chardan Capital	Reiterated Rating	Buy	$10.00	High	i Rating by Geulah Livshits at Chardan Capital
3/25/2021	HC Wainwright	Boost Price Target	Buy	$6.00 ➝ $8.00	High	i Rating by J. Pantginis at HC Wainwright
3/19/2021	HC Wainwright	Boost Price Target	Buy	$6.00 ➝ $8.00	Low	i Rating by J. Pantginis at HC Wainwright
3/11/2021	Oppenheimer	Reiterated Rating	Buy	$7.00	Medium	i
11/10/2020	HC Wainwright	Upgrade	Neutral ➝ Buy	$6.00	Medium	i Rating by J. Pantginis at HC Wainwright
10/6/2020	Noble Financial	Reiterated Rating	Buy	$6.60	High	i Rating by Cosme Ordonez at Noble Financial
7/28/2020	Alliance Global Partners	Boost Price Target	Buy	$4.00 ➝ $6.50	Medium	i
7/8/2020	Chardan Capital	Reiterated Rating	Buy	$10.00	Medium	i Rating by Geulah Livshits at Chardan Capital
5/27/2020	Alliance Global Partners	Initiated Coverage	Buy	$4.00	Low	i
5/14/2020	Noble Financial	Reiterated Rating	Buy	$5.45	Low	i Rating by Cosme Ordonez at Noble Financial
5/13/2020	HC Wainwright	Reiterated Rating	Hold		Medium	i Rating by J. Pantginis at HC Wainwright
4/30/2020	HC Wainwright	Reiterated Rating	Hold		High	i Rating by J. Pantginis at HC Wainwright
4/21/2020	Noble Financial	Reiterated Rating	Buy	$5.45	Low	i
3/30/2020	HC Wainwright	Downgrade	Buy ➝ Neutral	$7.00	Medium	i Rating by J. Pantginis at HC Wainwright
3/9/2020	Noble Financial	Initiated Coverage	Outperform	$5.45	High	i
12/23/2019	Chardan Capital	Reiterated Rating	Buy	$10.00	High	i Rating by Y. Livshits at Chardan Capital
11/5/2019	HC Wainwright	Initiated Coverage	Buy	$7.00 ➝ $7.00	High	i Rating by J. Pantginis at HC Wainwright
10/23/2019	Chardan Capital	Initiated Coverage	Buy	$10.00	High	i Rating by Y. Livshits at Chardan Capital

(Data available from 5/10/2016 forward)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Today's Range

Now: $4.48

$4.32

$4.80

50 Day Range

MA: $5.18

$4.21

$6.03

52 Week Range

Now: $4.48

$0.82

$7.30

Volume

10,271 shs

Average Volume

1,340,023 shs

Market Capitalization

$99.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.7

Frequently Asked Questions

What sell-side analysts currently cover shares of PDS Biotechnology?

The following Wall Street analysts have issued stock ratings on PDS Biotechnology in the last twelve months: Alliance Global Partners, Chardan Capital, HC Wainwright, Noble Financial, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for PDSB.

What is the current price target for PDS Biotechnology?

5 Wall Street analysts have set twelve-month price targets for PDS Biotechnology in the last year. Their average twelve-month price target is $7.62, suggesting a possible upside of 70.1%. Chardan Capital has the highest price target set, predicting PDSB will reach $10.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $6.50 for PDS Biotechnology in the next year.
View the latest price targets for PDSB.

What is the current consensus analyst rating for PDS Biotechnology?

PDS Biotechnology currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PDSB will outperform the market and that investors should add to their positions of PDS Biotechnology.
View the latest ratings for PDSB.

What other companies compete with PDS Biotechnology?

Other companies that are similar to PDS Biotechnology include MedAvail, Athenex, TherapeuticsMD, Geron, Seelos Therapeutics, Nature's Sunshine Products, Amryt Pharma, Oncorus, DURECT, Evolus, Spero Therapeutics, Puma Biotechnology, Hookipa Pharma, BeyondSpring and Fortress Biotech.

How do I contact PDS Biotechnology's investor relations team?

PDS Biotechnology's physical mailing address is 25B Vreeland Road, Florham Park NJ, 07932. The company's listed phone number is 800-208-3343 and its investor relations email address is [email protected] The official website for PDS Biotechnology is www.pdsbiotech.com.